Navigation Links
Inverness Medical Innovations Declares Dividend on its Series B Convertible Perpetual Preferred Stock
Date:9/15/2008

WALTHAM, Mass., Sept. 15 /PRNewswire-FirstCall/ -- Inverness Medical Innovations, Inc. (Amex: IMA), a leading provider of near-patient diagnostics, monitoring and health management solutions, today declared a dividend of $4.77 per share on its Series B Convertible Perpetual Preferred Stock (Amex: IMA.PR.B). The dividend will be paid in shares of Series B stock in an amount per share equal to the quotient of (a) $4.77 divided by (b) 97% of the average of the volume-weighted average price per share of the Series B stock on the American Stock Exchange for each of the five consecutive trading days ending on the second trading day immediately prior to the record date of the dividend. Inverness will pay cash in lieu of any fractional shares resulting from the dividend. The dividend is payable on October 15, 2008 to holders of record of Series B stock at the close of business on October 1, 2008.

This is the first dividend that the Company has declared and will pay on its Series B stock, and such payment will cover the amount of all dividends accrued from May 9, 2008, the original issuance date of the Series B stock, through September 30, 2008.

For more information about Inverness Medical Innovations, please visit our website at http://www.invernessmedical.com.

By developing new capabilities in near-patient diagnosis, monitoring and health management, Inverness Medical Innovations enables individuals to take charge of improving their health and quality of life. A global leader in rapid point-of-care diagnostics, Inverness' products, as well as its new product development efforts, focus on infectious disease, cardiology, oncology, drugs of abuse and women's health. Inv
'/>"/>

SOURCE Inverness Medical Innovations, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
2. Inverness - Chemogen Establish Exclusive License for TB Antibodies
3. Inverness Medical Innovations Announces Proposed Public Offering of Common Stock
4. Inverness Medical Innovations Agrees to Acquire ParadigmHealth
5. Inverness Medical Innovations Acquires ParadigmHealth
6. Inverness Medical Innovations to Participate at JP Morgan Healthcare Conference on January 8, 2008
7. Inverness Medical Innovations to Participate at 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008
8. Correction to Press Release Dated January 31, 2008: Inverness Medical Innovations to Participate at 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008
9. Inverness Medical Innovations Completes Acquisition of BBI Holdings Plc
10. Inverness Medical Innovations Announces Fourth Quarter 2007 Results
11. Inverness Medical Innovations to Participate at Bank of America 2008 Smid Cap Conference on March 26, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... United States (PRWEB) September 16, 2014 ... Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies is ... This report focuses on the three principal types ... of research and development in cancer immunotherapy (which ... inhibitors, Therapeutic anticancer vaccines and Adoptive cellular immunotherapy. ...
(Date:9/15/2014)... fast when a patient has sepsis, a life-threatening condition ... blood -- often too fast for antibiotics to help. ... developed by a team at Harvard,s Wyss Institute for ... treat sepsis. , "Even with the best current ... at least 30 percent of the time," said Mike ...
(Date:9/15/2014)... Sept. 15, 2014 Zymo Research Corp., has ... solution for safe ambient temperature storage and transport ... the infectivity of agents in such samples is ... integrity of the viral nucleic acids for subsequent ... Ebola epidemic in West Africa ...
(Date:9/15/2014)... CA (PRWEB) September 15, 2014 ... term implantable silicones for the medical device and ... silicone gel for the implantable medical device market. ... unique crosslink technology delivering a silicone gel with ... The Dual Matrix technology consists of two crosslinked ...
Breaking Biology Technology:Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 2Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 4Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 5Blood-cleansing biospleen device developed for sepsis therapy 2Blood-cleansing biospleen device developed for sepsis therapy 3Blood-cleansing biospleen device developed for sepsis therapy 4Safe storage and transport of Ebola, Mers-CoV, and other viruses: Groundbreaking viral inactivation solution capable of preserving nucleic acids 2Safe storage and transport of Ebola, Mers-CoV, and other viruses: Groundbreaking viral inactivation solution capable of preserving nucleic acids 3Applied Silicone Launches Silicone Gel System with Dual Matrix Technology 2
... programs for the University of Wisconsin-Madison, is part information technologist, ... Part II of this interview. In Part I , ... (below), he addresses creating a culture of innovation and finding ... featured speaker at the Fusion 2007 CEO-CIO Symposium . ...
... In a move that could bring additional investment partners to ... an office in Ann Arbor, Mich. after receiving money from ... which recently moved into a larger space in the MGE ... of three venture firms selected to receive funding through a ...
... - Oskar Anderson, chief information officer for the Wisconsin ... succeed Matt Miszewski as administrator of the state Division ... this week, will join the Department of Administration ... His appointment was confirmed this morning in an e-mail to ...
Cached Biology Technology:Venture Investors to open Michigan office 2Oskar Anderson to succeed Miszewski as head of state technology division 2
(Date:9/16/2014)... "molecular brakes" that time the generation of important cells ... cells" translate sound waves into electrical signals that are ... If the arrangement of the cells is disordered, hearing ... will be published in The Journal of Neuroscience ... Hey2 act as brakes to prevent hair cell generation ...
(Date:9/16/2014)... the dinosaurs 66 million years ago decimated the evergreens ... than their deciduous peers, according to a study led ... journal PLOS Biology . , Applying biomechanical ... leaves of angiosperms flowering plants excluding conifers ... of a diverse plant community thriving during a 2.2 ...
(Date:9/16/2014)... returned to Spain culminating the around the world of ... of how the global ocean works and what is ... the atmosphere is not limited to coastal areas, but ... planet, and it is already affecting the ocean ecosystem. ... CSIC Residence for Researchers in Barcelona, in a congress ...
Breaking Biology News(10 mins):Hey1 and Hey2 ensure inner ear 'hair cells' are made at the right time, in the right place 2Meteorite that doomed dinosaurs remade forests 2Meteorite that doomed dinosaurs remade forests 3Meteorite that doomed dinosaurs remade forests 4The Malaspina Expedition confirms that pollution reaches even the most remote areas of the ocean 2The Malaspina Expedition confirms that pollution reaches even the most remote areas of the ocean 3
... research team from Rollins College in Florida and the University ... the coral-killing pathogen that causes white pox disease of Caribbean ... elkhorn coral was listed for protection under the United States ... disease. The team,s findings have just been published in the ...
... A recent study demonstrated increased rates of celiac disease ... in the May-June 2011 issue of The Journal ... patients presenting with infertility. Each participant underwent serologic ... testing. The 4 patients who had positive serum ...
... , Cincinnati, (OH) - The International Rett Syndrome Foundation ... to support eight cutting-edge projects that aim to accelerate ... IRSF is the world,s largest private source of funding ... 1998, IRSF has cumulatively funded over $24M in high ...
Cached Biology News:Human pathogen killing corals in the Florida Keys 2Human pathogen killing corals in the Florida Keys 3IRSF awards over $650,000 for Translational Rett Syndrome research 2
... PP1, purified Formulation: 0.15M NaCl, ... 0.1mM MnCl2, 1mM MgCl2, 1mM EGTA, ... dephosphorylation of proteins Purification: DEAE chromatography, ... and gel filtration chromatography Quality Assurance: ...
... Endothelin-1 (human, porcine) Endogenous potent ... ETA receptor and modulates vascular tonus. ET-1, ... three distinct endothelin genes. ET-2 and ET-3 ... two and six amino acids, respectively. All ...
Human sVCAM-1/CD106 ELI-PAIR Kit...
HNF-1 Purified Anti-Mouse, Anti-Rat, Anti-Rabbit, Anti-Human clone 2, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
Biology Products: